Alliancebernstein L.P. bought a new stake in Neos Therapeutics, Inc. (NASDAQ:NEOS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,000 shares of the company’s stock, valued at approximately $161,000. Alliancebernstein L.P. owned about 0.10% of Neos Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new position in Neos Therapeutics in the second quarter valued at $102,000. OMERS ADMINISTRATION Corp bought a new position in Neos Therapeutics in the second quarter valued at $110,000. Rhumbline Advisers increased its stake in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after acquiring an additional 2,441 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Neos Therapeutics by 103.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after acquiring an additional 22,200 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Neos Therapeutics by 13.0% in the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after acquiring an additional 6,223 shares during the last quarter. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Neos Therapeutics, Inc. (NASDAQ:NEOS) opened at $10.95 on Wednesday. Neos Therapeutics, Inc. has a 12 month low of $4.85 and a 12 month high of $13.15. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.84 and a current ratio of 2.42.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.22. The company had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. analysts predict that Neos Therapeutics, Inc. will post -2.89 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “22,000 Shares in Neos Therapeutics, Inc. (NEOS) Purchased by Alliancebernstein L.P.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/22000-shares-in-neos-therapeutics-inc-neos-purchased-by-alliancebernstein-l-p/1703925.html.

A number of research analysts have recently issued reports on NEOS shares. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Wells Fargo & Company set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $14.00.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.